u/hugo_pires

eGFR from 14 to 4 is movement, not noise

the glucagon component changes the side effect profile, not just the efficacy Counter-anecdote: opposite result, same dose.

Disagree on that part. 98.7% and 95.1% on the same vial is normal.

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

Strongly agree. Escrow is non-negotiable for groups.

multiple batches from QYB show a spread, that is the data

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Slight fix: the number was 98.9, not 99.0. Decimal point, but a fairly consequential one.

Crossposting this to c/cagrilintide because the people who need it are not reading this community.

The research community is small on cagrilintide. Forum lore changes faster than data.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Yeah, the network selection matters most.

copay is separate from coverage

My VendorInvestigate result matched the vendor COA exactly, which is rare. SGN deserves that note in the directory.

Disagree.

Adding to this: ApoB is doing more work than the comment implies.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

Respectfully this is a sample of one presented as a finding.

network selection matters, wrong chain is the expensive typo

Maintenance for 2 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.

the 33 week mark is where it gets interesting

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.